Sugi Predict

Sugi Predict / Targets / MOK

MOK

MAPK/MAK/MRK overlapping kinase · Q9UQ07 · MOK on Sugi Atlas →

4,081 patent compounds predicted against MOK, 2,017 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5220954 SCHEMBL5220954 0.49 11/20
SCHEMBL3336361 SCHEMBL3336361 0.51 10/20
SCHEMBL3339873 SCHEMBL3339873 0.50 10/20
SCHEMBL3869547 SCHEMBL3869547 0.46 10/20
SCHEMBL4732598 SCHEMBL4732598 0.56 9/20
SCHEMBL4731923 SCHEMBL4731923 0.54 9/20
SCHEMBL5819962 SCHEMBL5819962 0.51 9/20
SCHEMBL4139048 SCHEMBL4139048 0.47 9/20
SCHEMBL4735359 SCHEMBL4735359 0.53 8/20
SCHEMBL4317695 SCHEMBL4317695 0.45 8/20
SCHEMBL5782943 SCHEMBL5782943 0.40 8/20
SCHEMBL2927675 SCHEMBL2927675 0.53 7/20
SCHEMBL4911258 SCHEMBL4911258 0.49 7/20
SCHEMBL3713979 SCHEMBL3713979 0.47 7/20
SCHEMBL946673 SCHEMBL946673 0.45 7/20
SCHEMBL2574195 SCHEMBL2574195 0.44 7/20
SCHEMBL2923640 SCHEMBL2923640 0.42 7/20
SCHEMBL4082535 SCHEMBL4082535 0.39 7/20
SCHEMBL5755497 SCHEMBL5755497 0.38 7/20
SCHEMBL5750675 SCHEMBL5750675 0.36 7/20

Clinical trials — most relevant to MOK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma PHASE2RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma PHASE2ACTIVE_NOT_RECRUITING
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer PHASE2RECRUITING
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule PHASE2NOT_YET_RECRUITING
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies PHASE1/PHASE2RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma PHASE1ACTIVE_NOT_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations PHASE1SUSPENDED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
RASopathy Biorepository nanRECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MOK binder may also engage these)

ProteinNameSimilarity
Q9WVS4 — 0.998 Q9WVS4 →
O54863 — 0.981 O54863 →
P49187 — 0.980 P49187 →
Q39050 — 0.977 Q39050 →
TSSK1B Testis-specific serine/threonine-protein kinase 1 0.976 landscape →
A0A0J9UVX2 — 0.975 A0A0J9UVX2 →
P62205 — 0.975 P62205 →
Q28GW8 — 0.974 Q28GW8 →
Q91821 — 0.974 Q91821 →
Q61241 — 0.974 Q61241 →
Q61831 — 0.974 Q61831 →
Q3SZW1 — 0.973 Q3SZW1 →
MELK Maternal embryonic leucine zipper kinase 0.973 landscape →
Q8BTH8 — 0.973 Q8BTH8 →
PLK2 Serine/threonine-protein kinase PLK2 0.972 landscape →
Q62762 — 0.972 Q62762 →
P47809 — 0.971 P47809 →
Q5ZJS0 — 0.971 Q5ZJS0 →
Q8BVP5 — 0.971 Q8BVP5 →
Q5R4L1 — 0.971 Q5R4L1 →
Q9Z265 — 0.971 Q9Z265 →
Q61846 — 0.971 Q61846 →
P40233 — 0.971 P40233 →
I1S050 — 0.971 I1S050 →
Q6NRT0 — 0.971 Q6NRT0 →
Q9R012 — 0.971 Q9R012 →
MAPK10 Mitogen-activated protein kinase 10 0.971 landscape →
Q6P5G0 — 0.970 Q6P5G0 →
TSSK2 Testis-specific serine/threonine-protein kinase 2 0.970 landscape →
Q93Z18 — 0.970 Q93Z18 →